
1. united european gastroenterol j. 2018 mar;6(2):213-224. doi:
10.1177/2050640617716607. epub 2017 jun 17.

treatment hepatitis c genotype 1 infection germany: effectiveness and
safety antiviral treatment real-world setting.

höner zu siederdissen c(1), buggisch p(2), böker k(3), schott e(4), klinker h(5),
pathil a(6), pfeiffer-vornkahl h(7), berg t(8), sarrazin c(9), hüppe d(10), manns
mp(1), mauss s(11).

author information: 
(1)hannover medical school, department gastroenterology, hepatology and
endocrinology, hannover, germany.
(2)ifi-institute interdisciplinary medicine, hamburg, germany.
(3)hepatologische praxis, hannover, germany.
(4)charité campus virchow-klinikum (cvk), berlin, germany.
(5)universitätsklinikum würzburg, würzburg, germany.
(6)universitätsklinikum heidelberg, heidelberg, germany.
(7)e.factum gmbh, butzbach, germany.
(8)universitätsklinikum leipzig, leipzig, germany.
(9)st. josef hospital, wiesbaden, germany.
(10)gastroenterologische gemeinschaftspraxis herne, herne, germany.
(11)center hiv hepatogastroenterology, düsseldorf, germany.

background: pivotal studies direct-acting antivirals (daas), rates of
sustained virological response hepatitis c genotype 1 infection >90%.
objective: objective article assess real-world safety and
effectiveness daa treatment prospective multicenter registry study.
methods: german hepatitis c-registry includes 6606 patients genotype 1
from 246 centers, treated february 2014 june 2016 discretion
of physician.
results: total 4846 patients completed treatment follow-up; 51% these
patients treatment experienced 28% liver cirrhosis. comorbidities
were reported 76% patients, including hiv co-infection 8%. svr12 92%
with 91% gt1a 93% gt1b. hiv co-infected patients (n = 247) svr12
of 92%. treatment discontinued prematurely 2.5%. multivariate analysis,
svr12 dependent choice antiviral regimen (or 1.33 (1.24-1.43);
p < 0.001), negatively associated presence liver cirrhosis (or 0.71
(0.56-0.89); p < 0.003) positively associated female gender (or 1.52
(1.21-1.91); p < 0.001).
conclusion: data real-world registry show svr12 rates close those
obtained clinical studies. discontinuation rates low, confirming good
tolerance regimens good adherence patients (trial registration
number drks00009717, german clinical trials register, drks).

doi: 10.1177/2050640617716607 
pmcid: pmc5833224
pmid: 29511551 

